Sonova Holding (OTCMKTS:SONVY) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Sonova Holding (OTCMKTS:SONVY) have received a consensus rating of “Hold” from the nine research firms that are covering the stock, MarketBeat.com reports. Three analysts have rated the stock with a sell recommendation, four have given a hold recommendation, one has given a buy recommendation and one has assigned a strong buy recommendation to the company.

SONVY has been the topic of several recent research reports. Rothschild Redb upgraded Sonova from a “strong sell” rating to a “hold” rating in a report on Monday, October 6th. Zacks Research lowered Sonova from a “hold” rating to a “strong sell” rating in a report on Tuesday, December 9th. BNP Paribas Exane began coverage on Sonova in a report on Monday, October 20th. They issued an “underperform” rating for the company. Finally, Royal Bank Of Canada raised Sonova to a “moderate buy” rating in a research report on Tuesday, November 18th.

Sonova Stock Performance

Sonova stock opened at $54.89 on Thursday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 0.91 and a current ratio of 1.24. Sonova has a 1-year low of $47.55 and a 1-year high of $71.50. The firm’s fifty day simple moving average is $52.07 and its 200-day simple moving average is $54.78.

Sonova Company Profile

Sonova AG (OTCMKTS:SONVY) is a Switzerland-based provider of hearing care solutions, headquartered in Stäfa. The company designs, develops, manufactures and distributes a range of audiological products and related services aimed at improving hearing and communication for people with hearing loss. Its portfolio spans behind-the-ear and in-the-ear hearing instruments, wireless accessories and software solutions that enable connectivity with consumer devices and audiological fittings.

Sonova markets its products under several well-known brands, including Phonak and Unitron for hearing aids, and it is also associated with Advanced Bionics for cochlear implant systems.